Pfizer Inc. Says Will Take 1-3 Years To Get HDL-Drug Data

October 21, 2005 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

NEW YORK, Oct 20 (Reuters) - Pfizer Inc. (PFE.N: Quote, Profile, Research) on Thursday said it will take one to three years to amass necessary clinical trial data for its cholesterol drug torcetrapib, the most important of its experimental drugs.

Twitter
LinkedIn
Facebook
Email
Print

Clinical research Phase 2

Pfizer